Experimental methods to investigate the mechanism of APPL1 acting on Rab32

By studying the interaction between APPL1 and Rab32, mitochondrial division is inhibited and activate the APPL1/Rab32/p-Drp1Ser637 signaling pathway, the problem of insulin resistance in the brain after sleep deprivation is solved, and the cognitive function and neurological recovery of sleep deprivation mice was significantly improved.

CN117388505BInactive Publication Date: 2024-11-22THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311333384.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-16
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem of insulin resistance in the brain after sleep deprivation, especially in the abnormal mitochondrial division and the fusion mechanism are not clear, and there is a lack of effective therapeutic targets.

Method used

By studying the interaction between the adiponectin receptor APPL1 and Rab32, it inhibits mitochondrial division, activates the APPL1/Rab32/p-Drp1Ser637 signaling pathway, promotes mitochondrial fusion, and thus improves brain insulin resistance after sleep deprivation.

Benefits of technology

Through molecular docking, co-immunoprecipitation and behavioral experiment verification, APPL1 significantly improves the cognitive function and insulin resistance of mice after sleep deprivation by inhibiting mitochondrial division, increases mitochondrial fusion, reduces fragmentation, and improves neural function recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117388505B_ABST
    Figure CN117388505B_ABST
Patent Text Reader

Abstract

The present invention relates to a research method for improving brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission of APPL1. In vivo inflammation was performed on the insulin resistance in the brain of mice after sleep deprivation. ELSIA detection was used to find that the inflammatory factors in the brain of SD mice increased, the insulin secretion in brain tissue and blood increased, and glucose tolerance and insulin resistance occurred. In addition, the role of APPL1 after sleep deprivation was also verified in vivo. Immunofluorescence staining, transmission electron microscopy and protein imprinting experiments were used to find that up-regulating APPL1 expression significantly inhibited mitochondrial fragmentation and increased the expression of related proteins that promoted fusion; tail suspension experiments, open field experiments, novel object recognition experiments and Y-maze experiments were used to find that up-regulating APPL1 expression significantly improved the cognitive function of sleep-deprived mice, providing a reference for the treatment of cognitive disorders caused by neuroinflammation and insomnia and the development of drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to an experimental method for improving brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission through adiponectin receptor APPL1. Background Art

[0002] Sleep is an important part of healthy brain function, and chronic lack of sleep affects human brain function. Studies have found that neuroinflammation caused by insomnia reduces the central sensitivity to insulin and produces brain insulin resistance, which is one of the important factors leading to cognitive dysfunction. Mitochondria are key organs involved in inflammation and insulin resistance in neurons. A large number of studies have verified that under the action of inflammation (Alzheimer's disease, etc.), mitochondrial fragments in neurons increase, mitochondrial endoplasmic reticulum functional units (MAMs) decrease, and promoting mitochondrial fusion and inhibiting mitochondrial fission can effectively improve brain insulin resistance and promote neurological function recovery. It can be seen that inhibiting mitochondrial fission and increasing MAM membranes are key means to effectively improve neurological dysfunction caused by lack of sleep. At present, the molecular mechanism of mitochondrial fusion is still in the research stage, and it is urgent to explore new therapeutic targets.

[0003] The adiponectin receptor APPL1 (Adaptor Protein containing PH Domain, PTB Domain, and Leucine zippermotif 1) is a protein closely related to cell signal transduction and metabolic regulation. Among them, the interaction between APPL1 and Rab GTPases plays an important role in a variety of biological processes. Studies have confirmed that APPL1 can bind to the Bar region of Rab5 Rab22, regulate the vesicle transport and membrane fusion process in the cell membrane and cells, and participate in the endocytosis of cells and the formation of cell polarity. In addition to affecting the vesicle transport and endocytosis process, APPL1 activates the protein kinase A / cAMP response element binding protein (PKA / CREB) pathway through Rab5, participates in regulating cell proliferation, survival and transcription, and affects cell function and physiological processes. Rab32 / p-Drp1 Ser637 It is a classic pathway that promotes mitochondrial fusion. The activation of Rab32 is involved in the regulation of mitochondrial fusion. When Rab32 is in the GTP-bound state, it can interact with mitochondrial fusion proteins (such as Mfn1 and Mfn2) to promote fusion between mitochondria. In addition, Rab32 can interact with MFN2-Interacting Protein (Miro) and participate in regulating the interaction between mitochondria and microtubules. Our preliminary experiments found that after sleep deprivation, Rab32 and p-Drp1 Ser637 Both were significantly downregulated, indicating that Rab32 / p-Drp1 Ser637The pathway is an important target for treating sleep-related personality neurological dysfunction, but the upstream regulatory mechanism of this pathway is not clear.

[0004] Rab32 is a homologous isomer of the Rab family and also contains a Bar domain that can bind to APPL1. Therefore, we speculate that APPL1 may be the upstream molecular mechanism of Rab32. In addition, adiponectin, the activating substance of APPL1, is an insulin sensitizer normally secreted by the human body and is easier to detect and obtain clinically. Therefore, exploring the regulatory effect of APPL1 on Rab32 has important clinical therapeutic value. Summary of the invention

[0005] In view of the technical problems existing in the prior art, the purpose of the present invention is to provide a research method for improving brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission through adiponectin receptor APPL1, and confirming the regulatory relationship between APPL1 and Rab32 through molecular docking and immunoprecipitation. This technology is a cutting-edge technology in the research field, and verifies the structure and relationship of the two from multiple aspects through molecular structure and protein interaction, and the results are highly credible.

[0006] The technical implementation scheme of the present invention is:

[0007] The present invention provides a research method for improving brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission through adiponectin receptor APPL1, comprising the following steps:

[0008] Step 1: First, the molecular docking method is used to predict that APPL1 and Rab32 form a stable chemical structure;

[0009] Step 2: Then, co-immunoprecipitation was used to verify that APPL1 can regulate Rab32;

[0010] Step 3: SDS-PAGE electrophoresis was then used to verify that APPL1 was the upstream regulatory molecule of Rab32, and upregulation of APPL1 activated Rab32 / p-Drp1 Ser637 signaling pathways;

[0011] Step 4: Then, an ELISA test was performed to verify the presence of insulin resistance in the brain of mice after SD;

[0012] Step 5: Behavioral experiments were performed to verify that the cognitive function of SD mice was significantly improved after upregulating APPL1;

[0013] Step 6: Finally, immunofluorescence staining was used to verify that upregulation of APPL1 expression increased mitochondrial fusion and reduced fragmentation.

[0014] As a preferred method of this scheme, the specific operation of step 1 is as follows:

[0015] The protein structures of APPL1 and RAB32 were obtained from the PDB database, and the Zdock algorithm was used to study the interaction pattern of APPL1 and RAB32. The docking results showed that the Zdock docking score of PRKACA and LKB1 was 1889.287. Then Pymol 2.3.0 was used to analyze the interaction pattern of the docking results.

[0016] As another preferred method of this solution, the specific operation of step 2 is as follows:

[0017] Step 201: Obtain primary cortical neurons from C57BL / 6 mice

[0018] C57BL / 6 mice were killed 1 day after birth, and the mouse brains were taken out. The meninges and blood vessels were carefully peeled off under a microscope, and the cerebral cortex and hippocampus tissues of the mice were collected; the tissues were finely minced with microtweezers and subjected to cell digestion. After the digestion was terminated, the cells were filtered with a 200-mesh filter and centrifuged at 1000 rpm for 10 minutes to obtain primary cortical astrocytes. The cells were resuspended and inoculated in a pre-packaged 10 cm cell culture dish containing 10 mL of culture medium, and placed in an incubator at 37°C in a humidified 5% CO2 / 95% air environment; the culture medium was replaced every 3 days, and the cells were scraped off to extract protein after the cells covered the bottom of the culture dish;

[0019] Step 202: Extracting Cellular Proteins

[0020] Discard the upper culture medium, gently rinse the culture dish with PBS for 3 times, use a micropipette to remove the remaining liquid, add RIPPA lysis buffer to each culture dish, and use a cell scraper to collect the cells on one side of the culture dish. After standing for 30 minutes, suck the cells into a pre-cooled centrifuge tube, sonicate 3 times with an ultrasonic oscillator, centrifuge at 12000-14000 rpm for 10 minutes at 4°C, and keep the supernatant;

[0021] Step 203: BCA protein quantification to 1 mg;

[0022] Step 204: adding 80 μL of the control agarose resin slurry to the centrifugal column, and centrifuging the column to remove the storage buffer;

[0023] Step 205: Add 100 μL of buffer to the centrifugal column, centrifuge and discard the flow-through liquid;

[0024] Step 206: Add 1 mg of protein to the spin column containing the resin and incubate at 4°C for 1 hour with rotation;

[0025] Step 207: discard the spin column containing the resin after centrifugation and retain the flow-through liquid;

[0026] Step 208: mixing 10 μg APPL1 antibody with the flow-through;

[0027] Step 209: incubating at 4°C overnight to form an immune complex;

[0028] Step 210: Add the antibody / protein mixture sample to the washed Pierce Protein A / G agarose resin spin column and incubate on a shaker for 1 hour;

[0029] Step 211: centrifuging the column and retaining the flow-through liquid;

[0030] Step 212: Elute the antibody-bound proteins in the centrifugal column with 50ul of elution buffer, add 5x loading buffer to step 209 and step 210, and incubate at 100C for 10min;

[0031] Step 213: After the sample is cooled to room temperature, SDS-PAGE electrophoresis is performed.

[0032] Furthermore, the specific operations of step 3 are as follows:

[0033] Step 301: SDS gel electrophoresis and membrane transfer;

[0034] Step 302: After the transfer is completed, the PVDF membrane is immersed in 5% skim milk for 1 hour for blocking, followed by antibody incubation;

[0035] Step 303: Evenly drop the luminescent liquid on the cleaned PVDF membrane, turn on the Fusion X7 imaging luminescence system, and collect images.

[0036] Another object of the present invention is to provide a mechanism of action of APPL1 in regulating sleep personality neurological dysfunction. APPL1 regulates sleep personality neurological dysfunction through Rab32 / p-Drp1 Ser637 The signaling pathway promotes mitochondrial fusion and inhibits mitochondrial fission to improve brain insulin resistance after sleep deprivation.

[0037] Another object of the present invention is to provide the use of APPL1 in preparing a drug for treating sleep personality neurological dysfunction.

[0038] Another object of the present invention is to provide the use of APPL1 in preparing drugs for treating neuroinflammation.

[0039] Compared with the prior art, the present invention has the following advantages:

[0040] 1. The research method of APPL1 in the present invention improves brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission. In vivo inflammation was performed on the insulin resistance in the brain of mice after sleep deprivation. Blood glucose and ELSIA tests were used to find that inflammatory factors in the brain of SD mice increased, insulin secretion increased, and glucose tolerance and insulin resistance occurred. In addition, the role of APPL1 after sleep deprivation was also verified in vivo. Tail suspension test, open field test, new object recognition test and Y maze test were used to find that upregulating APPL1 expression significantly improved the cognitive function of sleep-deprived mice.

[0041] 2. The present invention uses real-time Western Blot technology to detect APPL1, Rab32 and p-Drp1 in neuronal cells Ser637 Protein expression levels of APPL1, Rab32 and p-Drp1 were significantly increased after cells were treated with lipopolysaccharide (LPS) compared with those in the control group. Ser637 The expression levels of proteins were significantly downregulated; after adding APPL1 activator, APPL1, Rab32 and p-Drp1 in LPS group Ser637 Protein expression was significantly upregulated. In addition, we confirmed the chemical binding and regulatory relationship between APPL1 and Rab32 through molecular docking and CO-IP technology, providing a reference for the treatment of neuroinflammation and drug development.

[0042] 3. The activator adiponectin (ADP) used in the research method of APPL1 in the present invention to improve brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission has the characteristics of being green and environmentally friendly, low in production cost, and simple in processing technology. The most important thing is that it is a natural secretion product of the human body, there is no clinical allergy and drug resistance, and there is no incompatibility. It has a good application prospect and is expected to become a potential drug for cognitive dysfunction caused by insomnia. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 Schematic diagram of the predicted stable molecular structure of APPL1 and Rab32;

[0044] Figure 2 The results of the co-immunoprecipitation CO-IP method to verify that APPL1 can regulate Rab32; (a) APPL1 binds to Rab32; (b) Rab32 binds to APPL1.

[0045] Figure 3In vitro verification of changes in primary neuronal mitochondria under inflammatory stimulation; (a) the expression of mitochondrial fusion proteins APPL1, Rab32, COX IV and P-Drp1 proteins decreased significantly after LPS stimulation of primary neurons; (b) immunofluorescence staining found that the expression of mitochondrial COX IV in neurons was significantly reduced under inflammatory conditions, and the distribution was fragmented; (c) staining of cytoskeletal proteins (Map2) and mitochondria (Mito tracker) found that under normal circumstances, mitochondria are in an aggregated state. After Lps inflammatory stimulation, mitochondria in neurons are distributed in a dotted state, which indirectly confirms that mitochondrial fragmentation increases under inflammatory conditions.

[0046] Figure 4 The figure shows the result of APPL1 agonist AdipoR1 (ADP) activating APPL1 / Rab32 / P-PKA / P-Drp1 pathway and inhibiting mitochondrial fragmentation. (a) Cell experiments found that the expression of APPL1, Rab32, COX IV and P-Drp1 proteins decreased significantly after LPS stimulation of primary neurons. After APPL1 activation, the mitochondrial fusion-related proteins Rab32, COX IV and P-Drp1 increased significantly. (b) Immunofluorescence experiments confirmed that after Lps stimulation, mitochondrial fragmentation in neurons increased significantly. After APPL1 activation (Lps+ADP), mitochondrial damage could be significantly reversed and mitochondrial fusion was promoted.

[0047] Figure 5 Up-regulating the expression of APPL1 significantly improved the insulin resistance and cognitive function of sleep-deprived mice; (a) the inflammatory factors IL-1α, TNF-α, IL-1β and IL-6 in the brain of SD mice after sleep deprivation were significantly higher than those in the control group; (b) the insulin level in the brain of SD mice was significantly upregulated; (cd) the glucose tolerance test (GTT) also found that the blood glucose baseline and area under the curve of SD mice were significantly increased compared with those before modeling; (ef) the insulin resistance (ITT) experiment found that SD mice had obvious insulin resistance; (g) in vivo experiments found that the expression of APPL1, Rab32, COX IV and P-Drp1 proteins was significantly decreased after SD, and after overexpression of APPL1, the mitochondrial fusion-related proteins Rab32, COX IV and P-Drp1 were significantly increased; (h) transmission electron microscopy also found that mitochondrial fission in SD mice was significantly increased.

[0048] Figure 6To verify whether APPL1 exerts its effect through downstream Rab32. First, through (a) mitochondrial membrane potential JC-1, it was found that the mitochondrial membrane potential was significantly reduced after Lps stimulation (red), and the membrane potential was significantly enhanced after APPL1 activation. (b) After the cells were transfected with Rab32 interference lentivirus and the expression of mitochondrial Rab32 was knocked out, it was found that the expression of antioxidant-superoxide dismutase (SOD) (c) increased significantly, and ADP could not increase the expression of SOD after Lps inflammatory stimulation. In addition, it was found that ADP could not improve the expression of antioxidant-glutathione peroxidase (GSH-Px) after inflammatory stimulation (d). It also could not reduce the expression of malondialdehyde (MDA), an important molecule involved in lipid peroxidation (e). The above confirmed that APPL1 regulates mitochondrial function through Rab32.

[0049] Figure 7 The effects of APPL1 on cognitive function of mice were evaluated. (a) Compared with SD mice, upregulation of APPL1 expression (OE group) significantly reduced the immobility time of SD mice in the tail suspension test; (b) In the Y maze, the number of correct cycles of mice in the SD+OE group was significantly increased compared with that of SD mice; (c) The new object recognition experiment found that the exploration time of mice in the SD+OE group was significantly prolonged; (d) The open field experiment found that the activity time of the central area of ​​SD mice was significantly reduced, and the mice in the SD+OE group significantly improved the depressive-like behavior of mice, and the activity time of their central area was significantly increased. DETAILED DESCRIPTION

[0050] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0051] Currently, the treatments for adult sleep disorders mainly include cognitive behavioral therapy and drug therapy. However, the efficacy of cognitive behavioral therapy or the duration of drug effects are limited. Since insufficient sleep is a predictable clinical symptom, it is urgent to find intervention targets in the early stages. Confirming the chemical binding and regulatory relationship between APPL1 and Rab32 may provide a new direction for the treatment of cognitive dysfunction caused by insomnia.

[0052] The research method of adiponectin receptor APPL1 improving brain insulin resistance after sleep deprivation by inhibiting mitochondrial fission includes the following steps:

[0053] Step 1: First, the molecular docking method is used to predict that APPL1 and Rab32 form a stable chemical structure;

[0054] Step 2: Then, co-immunoprecipitation was used to verify that APPL1 can regulate Rab32;

[0055] Step 3: SDS-PAGE electrophoresis was then used to verify that APPL1 was the upstream regulatory molecule of Rab32, and upregulation of APPL1 activated Rab32 / p-Drp1 Ser637 signaling pathways;

[0056] Step 4: Then, an ELISA test was performed to verify the presence of insulin resistance in the brain of mice after SD;

[0057] Step 5: Behavioral experiments were performed to verify that the cognitive function of SD mice was significantly improved after upregulating APPL1;

[0058] Step 6: Finally, immunofluorescence staining was used to verify that upregulation of APPL1 expression increased mitochondrial fusion and reduced fragmentation.

[0059] The specific operation of step 1 is as follows: the protein structures of APPL1 (PDB ID: 2Q12) and RAB32 (PDB ID: 4CTM) were downloaded from the PDB database, and the interaction pattern of APPL1 and RAB32 was studied using Zdock. The docking results showed that the Zdock docking score of PRKACA and LKB1 was 1889.287. The residues around the protein-protein interaction interface can form hydrogen bonds. These non-covalent bonds can help stabilize the protein-protein complex. Pymol 2.3.0 was used to analyze the interaction pattern of the docking results.

[0060] R46, Y203, H100, S215, T61, G230, and R237 of APPL1 form hydrogen bonds with R55, I58, K97, Q78, R76, H196, Q197, and D70 of RAB32, respectively, and the lengths of the hydrogen bonds are The above residues may be the active residues ( Figure 1 ).

[0061] Specific operations of step 2:

[0062] Step 201: Obtain primary cortical neurons from C57BL / 6 mice

[0063] C57BL / 6 mice were killed 1 day after birth, and the mouse brains were taken out. The meninges and blood vessels were carefully peeled off under a microscope, and the cerebral cortex and hippocampus tissues of the mice were collected; the tissues were finely minced with microtweezers and subjected to cell digestion treatment (0.25% trypsin, 37°C, 10 minutes). After the digestion was terminated, the cells were filtered with a 200-mesh filter and centrifuged at 1000 rpm for 10 minutes to obtain primary cortical astrocytes in the culture dish. The cells were resuspended and inoculated in a pre-packaged 10 cm cell culture dish containing 10 mL of culture medium (Neurobasal, B27, Glu, 20 U / mL penicillin and 20 pg / mL streptomycin), and the dish was placed in an incubator at 37°C in a humidified 5% CO2 / 95% air environment; the culture medium was replaced every 3 days, and the cells were scraped off to extract protein after the cells covered the bottom of the culture dish;

[0064] Step 202: Extracting Cellular Proteins

[0065] Discard the upper culture medium, gently rinse the culture dish with PBS for 3 times, use a micropipette to remove the remaining liquid, add RIPPA lysis buffer to each culture dish, and use a cell scraper to collect the cells on one side of the culture dish. After standing for 30 minutes, suck the cells into a pre-cooled centrifuge tube, sonicate 3 times with an ultrasonic oscillator, centrifuge at 12000-14000 rpm for 10 minutes at 4°C, and keep the supernatant;

[0066] Step 203: BCA protein quantification to 1 mg;

[0067] Step 204: Add 80 μL of the control agarose resin slurry to the centrifuge column, and centrifuge the column (1000 g, 1 min) to remove the storage buffer;

[0068] Step 205: Add 100 μL of buffer to the centrifugal column, centrifuge and discard the flow-through liquid;

[0069] Step 206: Add 1 mg of protein to the spin column containing the resin and incubate at 4°C for 1 hour with rotation;

[0070] Step 207: After centrifugation (1000 g, 1 min), the spin column containing the resin is discarded and the flow-through liquid is retained;

[0071] Step 208: mixing 10 μg APPL1 antibody with the flow-through;

[0072] Step 209: incubating at 4°C overnight to form an immune complex;

[0073] Step 210: Add the antibody / protein mixture sample to the washed Pierce Protein A / G agarose resin spin column and incubate on a shaker for 1 hour;

[0074] Step 211: centrifuging the column and retaining the flow-through liquid;

[0075] Step 212: Elute the antibody-bound proteins in the centrifugal column with 50ul of elution buffer, add 5x loading buffer to step 209 and step 210, and incubate at 100C for 10min;

[0076] Step 213: After the sample is cooled to room temperature, SDS-PAGE electrophoresis is performed (incubation with Rab32 antibody).

[0077] Specific operations of step 3:

[0078] Step 301: SDS gel electrophoresis and membrane transfer

[0079] First, fix the glass plate in the gel maker, align the lower ends of the two glass plates to prevent leakage, prepare the separation gel and concentration gel according to the instructions, insert the 10-hole comb, and try not to leave any bubbles. Move the glass plate to the electrophoresis tank and add the prepared electrophoresis solution. After pulling out the comb teeth, add 10μl of protein sample, and separate the protein with a voltage of 80V for the upper gel and 120V for the lower gel. After the protein is completely separated, take out the colloid, and fit it with the methanol-activated (1min) PVDF membrane according to the "sandwich" method, and transfer the membrane at a current of 300mA;

[0080] Step 302: Blocking and Antibody Incubation

[0081] After the transfer, the PVDF membrane was immersed in 5% skim milk for 1 hour, and the milk on the PVDF membrane was washed off with TBST solution, and the primary antibody dilution prepared according to the instructions was added, and incubated overnight in a shaker at 4°C refrigerator. The next day, the PVDF membrane was taken out and washed with TBST solution at room temperature (5min×3 times); the PVDF membrane was placed in the secondary antibody dilution solution, incubated on a shaker at room temperature for 1 hour, and then washed with BST solution (5min×3 times);

[0082] Step 303: Luminescent imaging: Evenly drop the luminescent liquid on the washed PVDF membrane, turn on the Fusion X7 imaging luminescent system, and collect images.

[0083] Specific operations of step 4:

[0084] Thaw the protein suspension on ice. While waiting for the thawing, place the kit at room temperature for 10-20 minutes. After sufficient preparation, add 300μl of washing solution to the well plate, let it stand for 1 minute, manually shake off the liquid in the well, pat dry on absorbent paper, and repeat washing 5 times. After drying the water, add 50μl to each well plate according to the order of the standard products marked in the kit (S0-S6). Il-1α concentration: 0, 3, 6, 12, 24, 48pg / mL; IL-6 concentration: 0, 10, 20, 40, 80, 160pg / mL; TNF-α concentration: 0, 40, 80, 160, 320, 640pg / mL; IL-1β concentration: 0, 7.5, 15, 30, 60, 120pg / mL; ADP concentration: 0, 5, 10, 20, 40, 80ng / mL. Add 10 μl of each sample to the sample well, and dilute the system to 50ul using the sample diluent in the kit. Except for the blank well, add 100 μL of the corresponding inflammatory factor antibody labeled with horseradish peroxidase to each well, cover it with a sealing film, and incubate it in a 37°C incubator for 60 minutes. Discard the liquid and repeat the plate wash 5 times. Then add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 minutes. Use 50 μL of stop solution to terminate the reaction, place the well plate in an enzyme reader, and measure the OD value of each well at a wavelength of 450 nm. In the Excel table, draw a linear regression curve of the standard according to the concentration of the standard and the corresponding OD value, and calculate the concentration of each sample according to the curve equation.

[0085] Specific operations of step 5:

[0086] Step 501: Y-maze test

[0087] First, we labeled the three arms of the maze as A, B, and C. The mice were placed in arm A and allowed to explore freely for 8 minutes. The number of times the mice entered all arms was recorded, and the number of correct alternations was calculated as a percentage, using the following formula: number of correct alternations (%) = (one complete alternation / (total number of arm entries-2)) × 100.

[0088] Step 502: New object recognition experiment

[0089] Mice were placed in a 40×40×50 cm square wooden box and allowed to freely explore the arena for 10 min without any objects. In the first test (familiarization phase), two identical objects were placed in the arena and mice were allowed to explore for 10 min. In the second test (test phase), one identical object was replaced by a new object (the shape and color were completely different from the old object), and mice were still allowed to freely explore the two new and old objects for 10 min. The time each mouse explored the different objects was recorded, and the proportion of time spent on the new object was calculated.

[0090] Novel object preference index = (time spent on the novel object / total time spent on both objects x 100) and distance to the central area (cm).

[0091] Step 503: The open field test

[0092] We tested mice in a 40 × 40 × 50 cm wooden box with a mark (20 × 20 cm) in the center of the box as the central area. The mice were placed in the center of the box and allowed to explore the test area for 15 min. The time and distance of the mice's activities into the central area and the surrounding area were recorded and analyzed.

[0093] Step 504: Tail suspension test

[0094] Place the mouse in the experimental environment and allow it to adapt for about 5 minutes. Fix the inelastic line or belt to the stand and make sure it is of moderate length. Wrap the inelastic line or belt around 1 / 3 of the mouse's tail and hang the mouse on the stand, making sure it cannot touch the ground or other objects. Start timing for 6 minutes, observe and record the behavior of the mouse during the hanging process and record the mouse's inaction time (hanging motionless) and struggling time.

[0095] Specific operations of step 6:

[0096] Wash the slides three times with PBS, prepare 0.3% Triton + 10% goat serum at 37°C, cover the brain tissue and seal for 30 minutes. After absorbing the liquid, incubate the prepared primary antibody on the brain tissue at 4°C overnight. Take out the slides on the second day and wash them on a PBS shaker for 1min / 3 times. After absorbing the water, add the fluorescent secondary antibody dilution and incubate at room temperature in the dark for 1h. Then carefully open the sealing box, drop DAPI, and incubate in the dark for 10min. Wash the slides again. After absorbing excess water, apply anti-fluorescence quencher to seal the slides, and then perform fluorescence photography.

[0097] Through the above series of experiments, the results confirmed that APPL1 can regulate the expression of Rab32 to form a stable molecular structure and form a regulatory relationship between the upstream and downstream ( Figure 1 and Figure 2 ); Studies have shown that the expression of APPL1 in the brain of sleep-deprived mice is significantly reduced. Upregulating the expression of APPL1 significantly improves insulin resistance and cognitive function in sleep-deprived mice ( Figure 5 ). Figure 5 a The results showed that the inflammatory factors IL-1α, TNF-α, IL-1β and IL-6 in the brain of SD mice were significantly increased after sleep deprivation compared with the control group. Figure 5 Insulin levels in the brain of bSD mice were significantly upregulated; Figure 5The c-5d glucose tolerance test (GTT) also found that the blood glucose baseline and area under the curve of mice after SD were significantly increased compared with those before modeling; (ef) The insulin resistance test (ITT) experiment found that mice after SD had obvious insulin resistance. In vivo experiments found that the expression of APPL1, Rab32, COX IV and P-Drp1 proteins decreased significantly after SD. After overexpression of APPL1, Rab32 and p-Drp1 Ser637 The expression of APPL1 was significantly increased, and mitochondrial fragmentation was reduced and fusion was increased (5g). 5h transmission electron microscopy also found that mitochondrial fission in SD mice was significantly increased. The above research results confirm that APPL1 can Ser637 The signaling pathway promotes mitochondrial fusion and improves mitochondrial function, thereby promoting neurological recovery after sleep deprivation.

[0098] Figure 3 After aLPS stimulation of primary neurons, the expression of mitochondrial fusion proteins APPL1, Rab32, COX IV and P-Drp1 decreased significantly; Figure 3 b Immunofluorescence staining showed that the expression of mitochondrial COX IV in neurons was significantly reduced under inflammatory conditions and was distributed in a fragmented manner; Figure 3 c Cytoskeletal protein (Map2) and mitochondrial staining (Mito tracker) revealed that, under normal circumstances, mitochondria were in an aggregated state. After Lps inflammatory stimulation, mitochondria in neurons were distributed in a dotted manner, which indirectly confirmed that under inflammatory conditions, mitochondrial fragmentation increased.

[0099] Cell experiments found that Figure 4 a), APPL1, Rab32, COX IV and P-Drp1 protein expressions were significantly decreased after LPS stimulation of primary neurons. After APPL1 activation, mitochondrial fusion-related proteins Rab32, COX IV and P-Drp1 were significantly increased; immunofluorescence experiments confirmed ( Figure 4 b) After Lps stimulation, mitochondrial fragmentation in neurons increased significantly. Activation of APPL1 (Lps+ADP) could significantly reverse mitochondrial damage and promote mitochondrial fusion.

[0100] First, by ( Figure 6 a) Mitochondrial membrane potential JC-1 found that mitochondrial membrane potential decreased significantly after Lps stimulation (red), and the membrane potential increased significantly after APPL1 activation. Figure 6 b After the cells were transfected with Rab32 interference lentivirus and the expression of mitochondrial Rab32 was knocked out, the antioxidant superoxide dismutase (SOD) ( Figure 6c) The expression level increased significantly, and ADP could not improve the expression of SOD after Lps inflammatory stimulation. In addition, it was found that ADP could not improve the expression of antioxidant glutathione peroxidase (GSH-Px) after inflammatory stimulation ( Figure 6 d). It also cannot reduce the expression of malondialdehyde (MDA), an important molecule involved in lipid peroxidation ( Figure 6 e). The above results confirm that APPL1 regulates mitochondrial function through Rab32.

[0101] ( Figure 7 a) Compared with SD mice, upregulation of APPL1 expression (OE group) significantly reduced the immobility time of SD mice in the tail suspension test; ( Figure 7 b) In the Y maze, the number of correct cycles of mice in the SD+OE group was significantly increased compared with that of SD mice; ( Figure 7 c) The new object recognition experiment found that the mice in the SD+OE group spent significantly longer time exploring new objects; ( Figure 7 d) The open field experiment found that the activity time of the central area of ​​SD mice was significantly reduced, while the depressive-like behavior of mice in the SD+OE group was significantly improved, and the activity time of the central area was significantly increased.

[0102] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. Use of adiponectin in the preparation of a drug for improving brain insulin resistance after sleep deprivation, characterized in that: Inhibiting mitochondrial fission through the adiponectin receptor APPL1 improves brain insulin resistance after sleep deprivation. APPL1 is an upstream regulatory molecule of Rab32. Upregulating APPL1 activates the Rab32 / p-Drp1Ser637 signaling pathway.